中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值作为肝细胞癌DEB-TACE术后肿瘤反应的预测因子
本回顾性研究纳入46例未接受过治疗的肝细胞癌患者,分析DEB-TACE术前中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)与影像组学特征、qEASL标准评估的肿瘤反应及无进展生存期(PFS)的关系。结果显示,高基线NLR和PLR可预测较差的肿瘤反应和较短PFS,并与非球形肿瘤生长相关。
要点
- 高基线NLR和PLR与DEB-TACE术后较差的容积增强肿瘤反应及较短PFS相关。
- 高NLR和PLR与治疗前MRI所示的非球形(非结节状)肿瘤生长相关。
- NLR、PLR为易获取的定量免疫生物标志物,可能有助于指导肝细胞癌局部治疗的个体化应用。
核心结论
- 本研究确立了定量炎症生物标志物的预后价值,其与侵袭性非球形肿瘤生长相关,并可预测DEB-TACE术后较差的肿瘤反应和较短PFS。
研究设计与样本
- 回顾性研究,纳入46例接受DEB-TACE的未治疗肝细胞癌患者。
- 治疗前实验室检查包括全血及分类计数、肝功能、甲胎蛋白水平。
- 分析NLR、PLR与治疗前增强MRI提取的影像组学特征、qEASL标准评估的肿瘤反应及PFS的相关性。
- 影像组学特征包括单结节肿瘤生长的球形度、动态对比增强行为、动脉期高增强和对比增强均匀性。
- 统计方法包括单变量和多变量线性回归、Cox回归和Kaplan-Meier分析。
关键影像表现/征象
- 高基线NLR和PLR与低肿瘤球形度(非球形肿瘤生长)相关(p=0.001和p<0.001)。
诊断标准与关键数值
- 肿瘤反应采用定量欧洲肝病研究协会(qEASL)标准评估。
- 高基线NLR预测较差肿瘤反应(p=0.014)和较短PFS(p=0.002)。
- 高基线PLR预测较差肿瘤反应(p=0.004)和较短PFS(p<0.001)。
临床应用与阅片要点
- 治疗前NLR和PLR可在常规血常规中获取,可能作为DEB-TACE术后肿瘤反应和PFS的预测指标。
- 治疗前MRI评估肿瘤球形度可能有助于识别高NLR/PLR相关的侵袭性生长模式。
- 作者指出该组定量免疫生物标志物可较容易地纳入临床指南,为肝细胞癌局部治疗的个体化应用和监测提供范式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the predictive value of quantifiable imaging and inflammatory biomarkers in patients with hepatocellular carcinoma (HCC) for the clinical outcome after drug-eluting bead transarterial chemoembolization (DEB-TACE) measured as volumetric tumor response and progression-free survival (PFS).
METHODS: This retrospective study included 46 patients with treatment-naïve HCC who received DEB-TACE. Laboratory work-up prior to treatment included complete and differential blood count, liver function, and alpha-fetoprotein levels. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were correlated with radiomic features extracted from pretreatment contrast-enhanced magnetic resonance imaging (MRI) and with tumor response according to quantitative European Association for the Study of the Liver (qEASL) criteria and progression-free survival (PFS) after DEB-TACE. Radiomic features included single nodular tumor growth measured as sphericity, dynamic contrast uptake behavior, arterial hyperenhancement, and homogeneity of contrast uptake. Statistics included univariate and multivariate linear regression, Cox regression, and Kaplan-Meier analysis.
RESULTS: Accounting for laboratory and clinical parameters, high baseline NLR and PLR were predictive of poorer tumor response (p = 0.014 and p = 0.004) and shorter PFS (p = 0.002 and p < 0.001). When compared to baseline imaging, high NLR and PLR correlated with non-spherical tumor growth (p = 0.001 and p < 0.001).
CONCLUSIONS: This study establishes the prognostic value of quantitative inflammatory biomarkers associated with aggressive non-spherical tumor growth and predictive of poorer tumor response and shorter PFS after DEB-TACE.
KEY POINTS: • In treatment-naïve hepatocellular carcinoma (HCC), high baseline platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are associated with non-nodular tumor growth measured as low tumor sphericity. • High PLR and NLR are predictive of poorer volumetric enhancement-based tumor response and PFS after DEB-TACE in HCC. • This set of readily available, quantitative immunologic biomarkers can easily be implemented in clinical guidelines providing a paradigm to guide and monitor the personalized application of loco-regional therapies in HCC.
引用
- Schobert IT, Savic LJ, Chapiro J, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. Eur Radiol. 2020. PMID: 32424595. doi:10.1007/s00330-020-06931-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。